Objective and design We designed a study to detect downstream phosphorylation targets of PKCb in MCP-1-induced human monocytes. Methods Two-dimensional gel electrophoresis was performed for monocytes treated with MCP-1 in the presence or absence of PKCb antisense oligodeoxyribonucleotides (AS-ODN) or a PKCb inhibitor peptide, followed by phospho-and total protein staining. Proteins that stained less intensely with the phospho-stain, when normalized to the total protein stain, in the presence of PKCb AS-ODN or the PKCb inhibitor peptide, were sequenced. Results Of the proteins identified, vimentin was consistently identified using both experimental approaches. Upon 32 P-labeling and vimentin immunoprecipitation, increased phosphorylation of vimentin was observed in MCP-1 treated monocytes as compared to the untreated monocytes. Both PKCb AS-ODN and the PKCb inhibitor reduced MCP-1-induced vimentin phosphorylation. The IP of monocytes with anti-vimentin antibody and immunoblotting with a PKCb antibody revealed that increased PKCb becomes associated with vimentin upon MCP-1 activation. Upon MCP-1 treatment, monocytes were shown to secrete vimentin and secretion depended on PKCb expression and activity. Conclusions We conclude that vimentin, a major intermediate filament protein, is a phosphorylation target of PKCb in MCP-1-treated monocytes and that PKCb phosphorylation is essential for vimentin secretion. Our recently published studies have implicated vimentin as a potent stimulator of the innate immune receptor Dectin-1 as reported by Thiagarajan et al. (Cardiovasc Res 99:494-504, 2013). Taken together our findings suggest that inhibition of PKCb regulates vimentin secretion and, thereby, its interaction with Dectin-1 and downstream stimulation of superoxide anion production. Thus, PKCb phosphorylation of vimentin likely plays an important role in propagating inflammatory responses.
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Background
Directed migration of inflammatory macrophages under the influence of chemoattractant cytokines, termed chemotaxis, is one of the key events in the pathogenesis of atherosclerosis. A group of small peptides known as chemokines, primarily responsible for this chemotaxis, are critically involved in directing activation and trafficking of leukocytes in both acute and chronic inflammation [2] [3] [4] [5] . Monocyte chemotactic protein-1 (MCP-1), a b-chemotactic cytokine secreted by the different types of arterial wall cells including endothelial cells, smooth muscle cells, macrophages and fibroblasts, plays an important role in atherogenesis by recruiting monocytes into the subendothelial cell layer [6] [7] [8] [9] [10] [11] . Strong evidence shows the critical role of MCP-1 in the subendothelial recruitment of monocytes and the subsequent progression of atherosclerotic lesion development [5, 6] . Upon extravasation into the subendothelial intimal space, monocytes differentiate into macrophages and acquire new functions [12, 13] . Accumulation of macrophages within plaques is a hallmark of this disease [14] . The MCP-1-deficient mice showed minimal lipid deposition and fewer macrophages within the artery walls [15] . Mice deficient in the receptor for MCP-1, chemokine receptor 2 (CCR2), display a phenotype similar to MCP-1-deficient mice with a pronounced defect in MCP-1-induced leukocyte strong adhesion to the endothelium and decreased leukocyte extravasation suggesting MCP-1 signaling via the CCR2 receptor [16] . Signaling pathways regulating the process, by which chemokines dynamically attract monocytes, modulate adhesion and transmigration are not yet well defined. Our lab has been investigating the signaling pathways involved in primary human monocyte chemotaxis, predominantly those regulating MCP-1 chemotaxis including serine/threonine protein kinases [15, [17] [18] [19] [20] .
Using pharmacologic inhibitors and isoform specific PKCa and b AS-ODN, we have shown previously that PKCb, not PKCa, mediates MCP-1-activated human monocyte chemotaxis [5] . In chronic stressful states like atherosclerosis and restenosis, induction of PKCb and other key molecules has been observed to mediate inflammation, migration and proliferation leading to injury and dysfunction of the vascular tissues [21, 22] . During hyperlipidemic conditions, PKCb activation has been shown to be a regulator of initiation and augment mechanisms involved in the progression of atherosclerosis. Assessment of the extent of activation of the PKCb isoform in apoE-/-mice implicates its contribution to the regulation of the pathogenesis in atherosclerosis. The PKCb accompanies intimal expansion as a vascular response to arterial injury during atherosclerosis as well as controlling MCP-1-induced chemotaxis [5, 23] . Studies showed that mice lacking both apoE and PKCb displayed significantly decreased atherosclerosis compared with apoE-null mice. And also apoE-null mice, fed chow containing the PKCb inhibitor ruboxistaurin, displayed significantly decreased atherosclerosis compared with the mice fed chow containing the vehicle as a control [24, 25] .
The aim of our study was to identify the downstream phosphorylation targets of PKCb in MCP-1-activated human monocytes to further our understanding of the mechanisms involved in PKCb regulation of inflammation. In this study, we have used the myristoylated PKCb inhibitor peptide and our previously characterized PKCb Sand AS-ODN as tools to identify PKCb substrates [5] .
Materials and methods

Materials
The PKCb inhibitor peptide was purchased from Promega (Madison, WI). The PKCb S-and AS-ODN were custom ordered from Invitrogen based on our previously published effective sequences (Carlsbad, CA). The MCP-1 was purchased from BD Biosciences and solubilized in 0.1 % BSA in DMEM (San Jose, CA). [ 32 P]-orthophosphate radionuclide (with specific activity 314-337 TBq/mMole) was purchased from Perkin Elmer (Waltham, MA). Primary antibodies used were V9 monoclonal antibodies from Sigma (St. Louis, MO), anti-vimentin antibody and phosphor (Ser) PKC substrate antibody from Cell Signaling (Danvers, MA), and rabbit anti-PKCb antibody (NBP2-12572) from Novus Biologicals (Littleton, CO). Human MCP-1 was purchased from BD Biosciences and diluted to 50 lg/mL with PBS containing 1 mg/mL BSA as a 1,000-fold stock solution and stored at -80°C.
Isolation of primary human monocytes and treatment of cells with the oligodeoxyribonucleotides and PKCb inhibitor peptide
Human monocytes were isolated from EDTA (3-4 mM) anticoagulated whole blood by sequential centrifugation over a Ficoll-Paque density solution to obtain mononuclear cells followed by platelet removal and adherence to tissue culture flasks precoated with bovine calf serum as previously described [26, 27] . The non-adherent cells were discarded and only the adherent cells were released with EDTA and washed twice with PBS and then used in experiments. This procedure yields [95 % monocytes as determined by FACS analysis. The efficacies of the PKCb isoenzyme-specific S-and AS-ODN used in our experiments were demonstrated in our previously published work [5] . The PKCb isoenzyme-specific antisense ODN sequence was 5 0 -AGC GCA CGG TGC TCT CCT CG-3 0 . Phosphorothioate-modified ODN were used for these experiments to prevent ODN degradation and all ODN were HPLC purified [5] . Either S-or AS-ODNs (10 lM) were added to the isolated human monocytes (2.5 9 10 6 cells/mL) suspended in polypropylene tubes DMEM with 10 % Bovine calf serum (BCS/DMEM) and incubated at 37°C in 10 % CO 2 for 24 h. The PKCb inhibitor peptide (10 lM) was added 30 min prior to the addition of MCP-1 (50 ng/mL). The MCP-1 was added during the last 30 min of incubation.
Preparation of cell lysates
After PKCb AS-or S-ODN treatment for 24 h, MCP-1 (50 ng/mL) was added to each tube and incubated for 30 min at 37°C. Cells were then treated with 1 mM sodium orthovanadate (Ipswich, MA) for 15 min to inhibit phosphatases, harvested, centrifuged and washed three times with PBS. The cells were then resuspended in lysis buffer (1 % Triton X-100 (Sigma, St. Louis, MO), and 1:100 diluted phosphatase inhibitor and protease inhibitor mixture (Sigma, St. Louis, MO). After 30 min on ice, the extracts were centrifuged at 9,3009g for 15 min at 4°C and the supernatants were collected as cell lysates. Two-dimensional gel electrophoresis of PKCb sense/ anti-sense ODN-treated primary human monocytes To obtain good protein separation for identification, 2-dimensional gel electrophoresis (DIGE) of primary human monocyte lysates was performed as previously described [28] . Cells were treated with MCP-1 in the presence or absence of PKCb AS-ODN. Protein concentrations of the cell lysates were determined by the BCA Protein Assay Kit (Pierce, Rockford, IL) and the 2-D Clean-Up Kit (Amersham Biosciences, Piscataway, NJ) was used to reduce non-protein impurities and to improve the quality of 2-DIGE results. The gels were stained with Pro-Q Diamond phosphoprotein gel stain (Invitrogen, Carlsbad, CA) for 90 min with gentle agitation in the dark and then destained for 30 min three times and washed with distilled water for another 10 min. After imaging the gels, they were placed directly into SYPRO Ruby protein gel stain Invitrogen (Carlsbad, CA) for total protein staining in the dark for overnight. The gels were then washed twice for 30 min. Gel imaging was performed after rinsing the gels with distilled water. Finally, the gels were stained with a visible non-fluorescent Coomassie blue (GelCode Blue) stain (Pierce, Rockford, IL) to aid in locating the proteins that are identified by comparison of the two gels stained with Pro-Q Diamond. Molecular masses were determined by simultaneously running standard protein markers. Phosphoproteins that stained with more intensity in the MCP-1 treated group as compared to the PKCb inhibitor peptide/PKCb AS-ODN treated group were cut from the gel, trypsinized, digested and analyzed by LC-mass spectrometry as described below. Immunoblots were probed with phosphor (Ser) PKC substrate antibody.
Liquid chromatography mass spectrometry (LC-MS)
To identify the proteins on gel pieces, LC-MS was performed as described [29] . For the protein digestion, the bands were cut from the gel and then dehydrated in acetonitrile, dried in a Speed-vac and digested with trypsin incubating overnight at room temperature. The peptides that were formed were extracted from the polyacrylamide in two aliquots of 30 lL 50 % acetonitrile with 5 % formic acid. The LC-MS system was a Finnigan LTQ linear ion trap mass spectrometer system. The digest was analyzed using the data dependent multitask capability of the instrument acquiring full scan mass spectra to determine peptide molecular weights and product ion spectra to determine amino acid sequence in successive instrument scans. This mode of analysis produces approximately 2,500 collisionallyinduced dissociation (CID) spectra of ions ranging in abundance over several orders of magnitude. The data were analyzed by using all CID spectra collected in the experiment to search the NCBI non-redundant database with the search program Mascot using a human taxonomy filter. All matching spectra were verified by manual interpretation. The interpretation process was aided by additional searches using the programs Sequest and Blast, as needed.
Metabolic labeling and vimentin immunoprecipitation
Isolated primary human monocytes (5 9 10 6 cells/2 mL/ well) were incubated in 10 % BCS/DMEM in the presence or absence of PKCb S-or AS-ODN for 20 h at 37°C in 10 % CO 2 . Cells were then preincubated in the phosphatefree DMEM for 1 h at 37°C in 10 % CO 2 . Cells were labeled with [ 32 P]-orthophosphate 100 lCi/mL for 3 h. The MCP-1 (50 ng/mL) was added to respective groups for 30 min, sodium orthovanadate (1 mM) was added for the last 15 min incubation. Cell lysates were immunoprecipitated with vimentin V9 antibody for 2 h and protein G agarose beads (Roche diagnostics, Indianapolis, IN) were added overnight at 4°C, both with constant rotation. Beads were washed and sample buffer was added prior to boiling for 5 min, followed by electrophoresis on 10 % SDSpolyacrylamide gel and transferred onto a polyvinylidene fluoride membrane [30] . Incorporation of [ 32 P] was determined by analysis with a phosphorimager before vimentin loading was verified by immunoblotting using antivimentin antibody and detected by enhanced chemiluminescence.
Vimentin immunoprecipitation
Human monocytes (5 9 10 6 cells/2 mL/well) were incubated in the presence or absence of the PKCb inhibitor peptide for 30 min followed by treatment with MCP-1 for 30 min and sodium orthovanadate (1 mM) was added for the final 15 min of incubation. The cell lysates were immunoprecipitated with anti-vimentin antibody followed by SDS-PAGE and transferred onto a polyvinylidene fluoride membrane [30] . Anti-PKCb antibody was used to detect the presence of PKCb. The membrane was stripped using a 20 mL stripping solution (100 mM 2-mercaptoethanol, 2 % (w/v) SDS, 62.5 mM Tris-HCl, pH 6.8) and reprobed with anti-vimentin antibody.
Detection of vimentin secretion
To determine whether MCP-1 promotes vimentin release from primary human monocytes, monocytes were treated with and without MCP-1, or with MCP-1 in the presence of PKCb S-ODN or AS-ODN or the myristoylated PKCb inhibitor peptide. Monocytes were then plated on a sixwell plate at a concentration of 5 9 10 6 cells/2 mL in Opti-MEM solution and incubated at 37°C with 10 % CO 2 for 48 h. This was followed by the treatment of PKCb S-and AS-ODN (5 lM) to the respective groups for the last 24 h. An hour before the end of the incubation, the inhibitor peptide (10 lM) was added to the corresponding group 30 min before the addition of MCP-1. The MCP-1 (50 ng/mL) and sodium orthovanadate were added 30 and 15 min to the respective groups before the end of the incubation, respectively. Supernatants were collected from each well, centrifuged at 1,0009g for 10 min to remove cell debris and the supernatants were concentrated in a centrifugal device (Amicon Ultracel 30 kDa) in the presence of protease inhibitors. The final concentrates were run on an SDS-PAGE, transferred onto a PVDF membrane and immunoblotted using anti-vimentin antibody. Recombinant human vimentin was used as a positive control.
Results
Vimentin is a potential substrate for PKCb phosphorylation in MCP-1-activated human monocyte chemotaxis
Prior studies in our lab showed that PKCb is required for human monocyte chemotaxis to MCP-1 [5] . To identify potential substrates for PKCb phosphorylation, we performed 2-DIGE on lysates of monocytes that were treated with MCP-1 in the presence or absence of specific antisense ODN to PKCb [5] . Monocytes were treated with MCP-1 in the presence and absence of PKCb AS-ODN. Figure 1 shows the SYPRO Ruby total protein and Pro-Q Diamond phosphoprotein stained gels. Figure 1a , b show the MCP-1 treated monocytes and Fig. 1c, d show the PKCb AS-ODN treated group. Figure 2 shows the same gel from Fig. 1a /c stained with Coomassie blue. The arrows point to proteins that stained with less intensity on phosphoprotein staining in the PKCb AS-ODN treated group. These proteins were cut from the gel, processed according to ''Materials and methods'' and sequenced using mass spectrometry. Twelve potential PKCb substrate proteins were located and identified (Table 1) . Among the 12 proteins, four of them included vimentin, an intermediate filament protein, migrating in the area outlined by the oval in Fig. 1 . Vimentin was consistently detected on sequencing in several repeat experiments. The varied migration of vimentin is likely due to alternative posttranslational modification since vimentin is highly phosphorylated. Two of the proteins (spot number 5 and 6) were identified as the capping protein gelsolin and two of the others were identified as biliverdin reductase, transaldolase, lasp-1 protein, annexin 1, lamin B1, L-plastin. The ovals on Fig. 1 indicate the area of the gel where vimentin was detected and phosphoprotein staining was remarkably decreased in the presence of PKCb antisense ODN. Although antisense-ODN provide a rather specific inhibition of PKCb expression, we used a complementary approach to identify potential PKCb substrates in MCP-1 activated monocytes. For these studies we used the PKCb inhibitor peptide (Promega) that blocks enzymatic activity. After 2-DIGE, immunoblots were probed with Phospho (Ser) PKC antibody as shown in Fig. 3a, b . Numerous Vimentin is a target of PKCb phosphorylation 995 differences were noted in the phosphorylation pattern. Pro-Q Diamond and SYPRO Ruby stains were used to stain phosphorylated proteins and all the proteins, respectively, in duplicate gels. Phosphoproteins that stained with less intensity in the presence of the PKCb inhibitor peptide when normalized for the total protein stain were visually located after Coomassie Blue staining of the gels, cut from the gel and processed as described in ''Materials and methods''. Figure 4 shows the Coomassie blue stained twodimensional gel after electrophoresis with protein extracts prepared from monocytes treated with MCP-1. The arrows point to the potential PKCb substrates. Thirteen proteins were identified by LC-MS and are listed in Table 2 .
MASCOT was used to analyze the data. As in the antisense-ODN experiments, vimentin was again identified as a potential substrate for PKCb phosphorylation. We chose to further investigate vimentin as it was identified consistently in numerous repeat experiments, showed very marked inhibition and displayed decreased phosphorylation in the presence of either the PKCb inhibitor peptide or AS-ODN specific for PKCb.
PKCb induces vimentin phosphorylation in MCP-1-activated human monocytes
To validate whether vimentin phosphorylation is indeed regulated by PKCb in MCP-1-activated human monocytes, the effect of PKCb on vimentin phosphorylation was examined in primary human monocytes labeled with [ 32 P]-orthophosphate. Monocytes were incubated with PKCb Sor AS-ODN followed by [ 32 P] labeling and subsequent MCP-1 activation. In the upper panel of Fig. 5a , phosphorylation of vimentin was detected using phosphorimage analysis of immunoprecipitated vimentin. In the lower panel of Fig. 5a , the vimentin content was analyzed by immunoblotting as a loading control. Although total vimentin appears to be elevated in Lane 4 of this blot, this was not seen in other experiments. To illustrate this, Fig. 5b shows the densitometric quantification of vimentin in the four different treatment groups of monocytes as the mean ± standard deviation for three similar experiments, Fig. 5c shows quantitative results of phosphorylation of vimentin in primary human monocytes upon activation with MCP-1 as compared with non-activated monocytes as the mean ± standard deviation for three similar experiments. Vimentin phosphorylation normalized to total vimentin was increased by treatment of human monocytes with MCP-1. This increase was ablated in monocytes that were deficient in PKCb expression due to specific AS-ODN treatment. Human monocyte lysates were fractionated by 2-DIGE and stained with ProQ Diamond phosphoprotein stain followed by SYPRO Ruby total protein stain and the ratios of phosphostaining to total protein in each gel spot were evaluated. Figure 4 shows the Coomassie blue stained two-dimensional gel after electrophoresis with lysates prepared from monocytes treated with MCP-1. The arrows point to the potential PKCb substrate proteins identified as described in ''Materials and methods''. These proteins showed decreased intensity on phosphoprotein staining as compared to total protein staining in the PKCb inhibitor peptide-treated group as compared to the MCP-1 treated group. The proteins were sequenced using liquid chromatography mass spectrometry and identified proteins are listed in Table 2 PKCb associates with vimentin upon treatment with MCP-1 in primary human monocytes Upon confirming that vimentin is a phosphorylation target of PKCb in MCP-1 treated primary human monocytes, we wanted to examine whether vimentin associates with PKCb upon MCP-1 treatment in monocytes. To investigate this, monocytes were left untreated, treated with MCP-1 or treated with MCP-1 and the PKCb inhibitor peptide. The lysates were immunoprecipitated with anti-vimentin antibody followed by immunoblotting with anti-PKCb antibody (Fig. 6a) . The blot was then stripped and reprobed with anti-vimentin antibody as shown in (Fig. 6b) . No association between PKCb and vimentin was observed in untreated monocytes yet MCP-1 treatment induced association (Fig. 6a) , thereby indicating the essential role of MCP-1 in inducing PKCb binding with vimentin. Treatment with the PKCb inhibitor peptide had no effect on the association between these two proteins; therefore, PKCb enzymatic activity is not required for association.
Detection of vimentin secretion by MCP-1 treated human monocytes
Vimentin, most commonly known for its functions as an intermediate filament protein, has recently been shown to be secreted by activated monocytes. Active secretion of vimentin has been observed to be upregulated in proinflammatory conditions and downregulated in antiinflammatory conditions [31] . Vimentin secretion appears to depend on its phosphorylation since secretion of vimentin was increased by the phosphatase inhibitor okadaic acid and inhibited by the PKC inhibitor GO6983. We, therefore, investigated whether MCP-1 induces vimentin secretion from monocytes and further whether PKCb is required for vimentin release. Upon treatment of isolated human monocytes with MCP-1, vimentin was secreted as shown in Fig. 7 . The MCP-1-induced secretion of vimentin by human monocytes was found to depend on PKCb expression and PKCb activity since both specific antisense ODN and the PKCb inhibitor peptide blocked secretion.
Discussion
The MCP-1 plays a key role in monocyte recruitment by promoting migration to the vessel wall; but the signal transduction pathways leading to migration and chemotaxis have not been fully elucidated. A newly developed fluorescent phosphosensor technology, the ProQ Diamond post-staining method that detects phosphoproteins in gels, to identify potential substrates for PKCb phosphorylation in MCP-1-activated primary human monocytes, was employed. For normalization we used SYPRO-Ruby, a total protein stain shown to be compatible with ProQ Diamond staining [32] . Of the proteins identified that stained with lesser intensity with the phosphostain in the presence of PKCb antisense ODN or a PKCb inhibitor peptide, vimentin was consistently present. Our study shows that vimentin phosphorylation is induced by MCP-1 activation of human monocytes. Vimentin retains a high level of sequence homology throughout all vertebrates from fish and Xenopus to humans strongly suggesting the physiological importance of vimentin [33] . During developmental stages, vimentin shows dynamically altered expression patterns and recent studies show involvement of vimentin in cell adhesion, migration, signaling and wound healing with distinct localization at the leading edge of keratinocytes migrating sheet [34] [35] [36] [37] . Vimentin has been reported to co-localize with transient actin-rich adhesion sites that participate in cell migration [38] . Vimentin also regulates integrin functions in endothelial cell adhesion and serves as a major contributor to leukocyte transmigration [39] [40] [41] . Although genetic knockout of vimentin in animal models showed no gross phenotypic abnormalities [42] , defects were observed in special physiological and pathological conditions including the observation that peripheral blood mononuclear cells showed reduced in vivo migration and diapedesis across the endothelium [35, 36] . Vimentin has additionally been shown to contribute to tumor cell invasiveness, metastasis and poor prognosis [43] [44] [45] [46] .
Organization of intermediate filament networks is observed to be primarily regulated and modulated by phosphorylation. The phosphorylation pattern of vimentin is highly complex involving different sites and kinases specific for unique cellular processes like differentiation, stress and mitosis [47] . Chemotactic factors such as formyl-peptides, have been shown to promote vimentin phosphorylation in vitro [48] and vimentin in neutrophils is phosphorylated upon stimulation with phorbol myristate acetate, strongly suggesting that it can be a substrate for PKC [49] . Indeed, vimentin has been reported to serve as a substrate for, and colocalize with several isoforms of PKC in varying cell types under certain conditions [50] [51] [52] [53] .
After identifying vimentin as a potential substrate for PKCb in MCP-1-activated human monocytes, our further studies, using [ 32 P] labeling and vimentin immunoprecipitation in the presence of specific antisense ODN to PKCb, validated our initial results (Fig. 5) . Furthermore, immunoprecipitation of monocyte lystates with an antibody to vimentin and immunoblotting with a PKCb antibody revealed that increased PKCb becomes associated with vimentin upon MCP-1 activation and this binding is independent of PKCb functional activity (Fig. 6 ). Although we are the first to report PKCb association with vimentin upon monocyte activation, others have previously observed a propensity for PKCb, among other PKC isoforms to colocalize with vimentin filaments. Taking all of these data together we conclude that vimentin associates with PKCb and is a target of PKCb phosphorylation in MCP-1-activated human monocytes and likely controls the mechanics of monocyte chemotaxis to MCP-1.
As mentioned in ''Results'', vimentin can also be secreted and secretion has been observed upon exposure to various activating stimuli in macrophages, platelets, neutrophils, T lymphocytes and endothelial cells [31, [54] [55] [56] . The physiological significance of released or secreted vimentin remains unknown. Secreted vimentin has been reported to induce the oxidative burst of macrophages since anti-vimentin antibody added to mature monocyte-derived macrophages reduced the superoxide anion production by these cells [31] . We have shown recently that soluble vimentin serves as a potent, endogenous ligand for the monocyte innate immune receptor, Dectin-1. We have also shown that binding of vimentin to Dectin-1 induces NADPH oxidase activity generating O 2 -in primary human monocytes [1] .
Conclusions
There is renewed interest in finding novel approaches for the treatment of chronic inflammatory diseases and understanding the role of chemokines in the recruitment of leukocytes to sites of inflammation; and it is, therefore, a focus of considerable research. Chemokine antagonists may stabilize established atherosclerotic plaques or cause them to regress in experimental animals. The PKCb inhibitor ruboxistaurine is currently being tested as a potential therapeutic target for chronic vascular stress and diabetes in ongoing pre-clinical and clinical trials yet the scope of PKCb contributions in atherogenesis have not been fully elucidated. These trials may provide a clearer picture as to whether this drug is a good option for PKCb inhibition, and whether this is an effective approach for treating cardiovascular disease, and particularly atherosclerosis [57, 58] . Alternatively antisense or RNA based therapies may prove effective. Recently, PKCb was found to correlate with increased NADPH oxidase activation exacerbating oxidative stress [59] . Our findings suggest that in addition to our findings that PKCb controls monocyte chemotaxis [5] , PKCb inhibition may prevent vimentin phosphorylation and its subsequent secretion by MCP-1 activated monocytes. This inhibition of extracellular vimentin may thereby interfere with the ability of extracellular vimentin to trigger superoxide anion production of monocyte/macrophages and limit oxidative stress in inflammatory sites. The PKCb activation and phosphorylation of vimentin, thus, plays a pivotal role in two major pro-inflammatory functions of human monocytes. 
